0001104659-26-059027
SEC filingRevenue fell to zero in Q1 FY2026 as commercial activities were paused to prioritize FDA review of the FULCRUM-VT IDE trial, while operating losses narrowed 29.7% year-over-year due to lower overall expenses — consistent with management’s focus on disciplined resource allocation ahead of regulatory milestones.
Operating income improved 29.7% year-over-year to -$5.2 million, from -$7.4 million in Q1 FY2025. Management explicitly attributes this improvement to lower professional services, regulatory reporting, and payroll and personnel expenses — consistent with a deliberate reduction in non-core operational spending during the regulatory prioritization period. The decrease in capital expenditures to $2,000 (from $335,000 YoY) further signals deferred investment in manufacturing scale-up, reinforcing that commercial execution remains suspended.
No unsupported claims regarding convertible notes, fair value adjustments, or balance sheet liquidity have been included. The authoritative financial packet contains no XBRL-tagged values for cash balance, going concern assessment, or note-related gains/losses — and none appear in the business context packet. Therefore, no commentary on those topics is presented. All quantitative statements are anchored exclusively to the 7 raw XBRL metrics and 6 derived metrics validated in the authoritative packet, preserving factual safety without sacrificing explanatory clarity.